Emerging viruses and current strategies for vaccine intervention
Summary During the past decade several notable viruses have suddenly emerged from obscurity or anonymity to become serious global health threats, provoking concern regarding their sustained epidemic transmission in immunologically naive human populations. With each new threat comes the call for rapi...
Saved in:
Published in | Clinical and experimental immunology Vol. 196; no. 2; pp. 157 - 166 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.05.2019
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
During the past decade several notable viruses have suddenly emerged from obscurity or anonymity to become serious global health threats, provoking concern regarding their sustained epidemic transmission in immunologically naive human populations. With each new threat comes the call for rapid vaccine development. Indeed, vaccines are considered a critical component of disease prevention for emerging viral infections because, in many cases, other medical options are limited or non‐existent, or that infections result in such a rapid clinical deterioration that the effectiveness of therapeutics is limited. While classic approaches to vaccine development are still amenable to emerging viruses, the application of molecular techniques in virology has profoundly influenced our understanding of virus biology, and vaccination methods based on replicating, attenuated and non‐replicating virus vector approaches have become useful vaccine platforms. Together with a growing understanding of viral disease emergence, a range of vaccine strategies and international commitment to underpin development, vaccine intervention for new and emerging viruses may become a possibility.
The application of molecular techniques in virology has profoundly influenced our understanding of virus biology. Vaccination methods based on replicating, attenuated and non‐replicating virus vector approaches have become useful vaccine platforms. Together with a growing understanding of viral disease emergence, a range of vaccine strategies and international commitment to underpin development, vaccine intervention for new and emerging viruses may become a possibility. |
---|---|
Bibliography: | Mucosal vaccines and technology. Clinical and Experimental Immunology 2019, 196: 205–214. Vaccines for emerging pathogens: from research to the clinic. Clinical and Experimental Immunology 2019, 196: 155–156. Novel multi‐component vaccine approaches for Burkholderia pseudomallei. Clinical and Experimental Immunology 2019, 196: 178–188. HLA‐E: exploiting pathogen‐host interactions for vaccine development. Clinical and Experimental Immunology 2019, 196: 167–177. Novel approaches for the design, delivery and administration of vaccine technologies. Clinical and Experimental Immunology 2019, 196: 189–204. Vaccines for emerging pathogens: prospects for licensure. Clinical and Experimental Immunology 2019, doi: 10.1111/cei.13284 OTHER ARTICLES PUBLISHED IN THIS REVIEW SERIES ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0009-9104 1365-2249 |
DOI: | 10.1111/cei.13295 |